Want to see TMDX full AI Analyst Report?
TMDX Stock Chart & Stats
$115.87
-$4.08(-5.19%)
At close: 4:00 PM EST
$115.87
-$4.08(-5.19%)
Day’s Range― - ―
52-Week Range$60.11 - $156.00
Previous CloseN/A
Volume1.17M
Average Volume (3M)992.31K
Market Cap
$2.54B
Enterprise Value$4.00K
Total Cash (Recent Filing)$461.74M
Total Debt (Recent Filing)$863.41M
Price to Earnings (P/E)14.6
Beta1.10
Next Earnings
Aug 04, 2026EPS Estimate
0.5Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)5.03
Shares Outstanding34,560,910
10 Day Avg. Volume759,292
30 Day Avg. Volume992,309
Financial Highlights & Ratios
PEG Ratio0.05
Price to Book (P/B)8.74
Price to Sales (P/S)6.83
P/FCF Ratio30.96
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda<0.01
Forecast
1Y Price Target
$123.88Price Target Upside6.91% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering9
EPS Forecast (FY)1.8
Revenue Forecast (FY)$732.29M
Bulls Say, Bears Say
Bulls Say
Improving Cash GenerationTTM free cash flow converting roughly 69% of net income signals durable cash generation capacity. That level of cash conversion supports funding R&D, fleet and international expansion without immediate equity raises, reducing reliance on capital markets over the medium term.
Consumable-driven Recurring RevenueBusiness model ties revenue to every transplant via single-use sets and services, creating a recurring per-case revenue stream. As installed base and utilization grow, consumable attach rates provide predictable, high-margin revenue that reinforces long-term revenue visibility.
Clear Multi-Front Growth RoadmapManagement's 20%–25% revenue guidance and multiple product/clinical initiatives (OCS upgrades, kidney Gen3 IDE, CHOPS IDE supplement, Europe NOP expansion) create several structural growth levers. Diversified initiatives reduce single-program dependency and extend the long-term addressable market.
Bears Say
Rising LeverageMaterial increase in leverage reduces financial flexibility and raises interest and refinancing risk if cash generation slows. Higher debt levels amplify downside sensitivity to margin compression or slower transplant volume, constraining optionality for opportunistic investments.
Near-Term Margin PressureFront‑loaded R&D, SG&A and inventory replenishment to support clinical programs and NOP expansion are compressing gross and operating margins. If investment cadence or supply costs persist, margin recovery will be delayed, reducing incremental return on growth initiatives for multiple quarters.
Execution And Volume RiskClinical enrollment delays and OPTN-driven donor volatility create persistent timing risk for case volumes and trial-dependent product adoption. These execution uncertainties can cause uneven revenue cadence, complicate scaling of consumables, and increase pressure on margins and cash flow predictability.
TransMedics Group News
TMDX FAQ
What was Transmedics Group’s price range in the past 12 months?
Transmedics Group lowest stock price was $60.10 and its highest was $156.00 in the past 12 months.
What is Transmedics Group’s market cap?
Transmedics Group’s market cap is $2.54B.
When is Transmedics Group’s upcoming earnings report date?
Transmedics Group’s upcoming earnings report date is Aug 04, 2026 which is in 13 days.
How were Transmedics Group’s earnings last quarter?
Transmedics Group released its earnings results on May 05, 2026. The company reported $0.3 earnings per share for the quarter, missing the consensus estimate of $0.598 by -$0.298.
Is Transmedics Group overvalued?
According to Wall Street analysts Transmedics Group’s price is currently Undervalued.
Does Transmedics Group pay dividends?
Transmedics Group does not currently pay dividends.
What is Transmedics Group’s EPS estimate?
Transmedics Group’s EPS estimate is 0.5.
How many shares outstanding does Transmedics Group have?
Transmedics Group has 34,560,910 shares outstanding.
What happened to Transmedics Group’s price movement after its last earnings report?
Transmedics Group reported an EPS of $0.3 in its last earnings report, missing expectations of $0.598. Following the earnings report the stock price went down -23.186%.
Which hedge fund is a major shareholder of Transmedics Group?
Currently, no hedge funds are holding shares in TMDX
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
TransMedics Group Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$123.88 (6.91% Upside)
$123.88 (6.91% Upside)
Blogger Sentiment
Bullish
TMDX Sentiment 70%
Sector Average 66%
Sector Average 66%
Hedge Fund Trend
Decreased
By 691.6K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Positive
Last 7 Days ▲ 0.6%
Last 30 Days ▲ 3.6%
Last 30 Days ▲ 3.6%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-33.13%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
71.32%
Trailing 12-Months
Company Description
Transmedics Group
TransMedics Group, Inc. operates as a commercial-stage medical technology enterprise, committed to transforming the landscape of organ transplant therapy for patients worldwide grappling with end-stage organ failure. At the core of their offerings is the Organ Care System (OCS), an innovative, portable solution engineered to perfuse, optimize, and continuously monitor donor organs. This system leverages exclusive, tailored technology to meticulously recreate near-physiological conditions for these vital organs while they remain outside the human body. The OCS suite encompasses specialized modules: OCS LUNG, which facilitates the preservation of standard criteria donor lungs for double-lung transplants; OCS Heart, designed for the extracorporeal perfusion and maintenance of donor hearts; and OCS Liver, dedicated to the preservation of donor livers. Founded in 1998, TransMedics is headquartered in Andover, Massachusetts.
TMDX Stock 12 Month Forecast
Average Price Target
$123.88
▲(6.91% Upside)
Technical Analysis
Ownership Overview
3.61% Insiders
42.76% Mutual Funds
2.75% Other Institutional Investors
23.25% Public Companies and Individual Investors